% | $
Quotes you view appear here for quick access.

Pharmacyclics, Inc. Message Board

  • jgmtruth jgmtruth Apr 16, 2013 12:49 PM Flag

    Johnson & Johnson Reports 2013 First-Quarter Results Tue, 04/16/2013 - 7:52am

    Johnson & Johnson today announced sales of $17.5 billion for the first quarter of 2013, an increase of 8.5% as compared to the first quarter of 2012. Operational results increased 9.8% and the negative impact of currency was 1.3%. Domestic sales increased 11.2 %. International sales increased 6.3%, reflecting operational growth of 8.7% and a negative currency impact of 2.4%. Also in the quarter, a New Drug Application was submitted to the FDA, as well as regulatory health authorities in Japan, seeking approval for simeprevir (TMC435), an investigational NS3/4A protease inhibitor, for the treatment of genotype 1 chronic hepatitis C in adult patients. In addition, the FDA granted Breakthrough Therapy Designations for the investigational oral agent ibrutinib as a monotherapy for three B-cell malignancies: in patients with relapsed or refractory mantle cell lymphoma who have received prior therapy; in patients with Waldenstrom's macroglobulinemia; and in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma with deletion of the short arm of chromosome 17. Ibrutinib is jointly being developed by Janssen Research & Development, LLC and Pharmacyclics Inc.

    Sentiment: Strong Buy

257.100.00(0.00%)Apr 23 3:59 PMEDT